Briefing Industry news Industry briefing NEWS Bayer agrees to pay $40m to resolve claims on three drugs Bayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims Act linked to three drugs, Trasylol, Avelox and Baycol, the US Department of Justice said in a press statement news Novartis announces plans to spin off Sandoz business Novartis has announced plans to completely spin off its generics and biosimilars division, Sandoz, to create a new publicly traded standalone firm Briefing FDA authorises Edgewise’s Phase II duchenne muscular dystrophy trial The US FDA granted authorisation for Edgewise Therapeutics’ Phase II clinical trial of EDG-5506 for treating duchenne muscular dystrophy (DMD) in children Industry news Industry briefing 09/14/2022 11:42:21
Briefing
FDA authorises Edgewise’s Phase II duchenne muscular dystrophy trial
The US FDA granted authorisation for Edgewise Therapeutics’ Phase II clinical trial of EDG-5506 for treating duchenne muscular dystrophy (DMD) in children